Normal view MARC view

NICE or nasty? Access and reimbursement of multiple sclerosis medicines in the UK

Author: Angelmar, Reinhard INSEAD Area: MarketingPublisher: Fontainebleau : INSEAD, 2006.Language: EnglishDescription: 35 p.Type of document: INSEAD CaseNote: Latest version available via https://publishing.insead.eduAbstract: NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.Pedagogical Objectives: Value pricing in the healthcare sector. Implications of value pricing for the main stakeholders (patients, physicians, payers, manufacturers). Implications of the adoption of cost effectiveness criteria by healthcare buyers for product development and international launch decisions of pharmaceutical companies.
Tags: No tags from this library for this title. Log in to add tags.
Item type Current location Collection Call number Status Date due Barcode Item holds
INSEAD Case Asia Campus
Archives
Print Consultation only BC007638
INSEAD Case Europe Campus
INSEAD Publications Display
Print Consultation only BC007637
Total holds: 0

Latest version available via <a href=https://publishing.insead.edu>https://publishing.insead.edu</a>

Value pricing in the healthcare sector. Implications of value pricing for the main stakeholders (patients, physicians, payers, manufacturers). Implications of the adoption of cost effectiveness criteria by healthcare buyers for product development and international launch decisions of pharmaceutical companies.

NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.

There are no comments for this item.

Log in to your account to post a comment.
Koha 18.11 - INSEAD Catalogue
Home | Contact Us | What's Koha?